Open AccessNIMOTUZUMAB INDUCED HYPERTENSION(NIH): A MAIDEN CASE REPORT
Author(s) -
Balaji Ommurugan,
Amita Priya,
Navin Patil
Publication year - 2017
Publication title -
asian journal of pharmaceutical and clinical research
Language(s) - English
Resource type - Journals
eISSN - 2455-3891
pISSN - 0974-2441
DOI - 10.22159/ajpcr.2017.v10i4.16868
Subject(s) - nimotuzumab , cetuximab , medicine , monoclonal antibody , bevacizumab , epidermal growth factor receptor , oncology , adverse effect , cancer , head and neck cancer , pharmacology , antibody , chemotherapy , immunology
Nimotuzumab is one among the latest humanized monoclonal antibody targeting against Epidermal Growth Factor Receptor (EGFR). It is approved for Head and neck squamous cancer in India, Srilanka, Cuba and Argentina, for glioma in Cuba, Argentina and Ukraine and Nasopharyngeal cancer in China. Hypertension is most common with Bevacizumab and Cetuximab, which are monoclonal antibodies against EGFR. Hence, we report here a case of Nimotuzumab induced hypertension in a 70-year-old man treated for vocal cord carcinoma. KEYWORDS: Nimotuzumab, Hypertension, EGFR, Adverse effects.